Human isotope fractional absorption studies comparing chelated Magnesium Glycinate vs. Citrate vs. 4% Oxide, CYP2R1/CYP27B1 magnesium-dependent Vitamin D3 activation trials, and Metformin-induced Vitamin B12 holotranscobalamin depletion. Explore 4,328 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Mean changes in diastolic and systolic BP were sustained for 44 weeks.
PS added to LLT can further improve lipid profile, without additional effects on intestinal sterol absorption or synthesis.
LPO levels were reduced in both statin arms after 16 weeks of treatment (p < 0.05 versus baseline), without changes in the placebo group.
This study has limitations, the main being that the search period was restricted to 5 years.
Improvement in immediate verbal memory exerted a direct influence on improvement in global function (p=0.006).
Our neuroimaging results bridge the gap between animal studies and human epidemiological studies of HT on cognition.
Based on an informal comparison with atorvastatin, this represents a three-fold greater potency.
The results of this comprehensive, prospective patient survey, along with findings from other similar reports, suggest that PVI provides an easy-to-use and convenient method for providing the necessary luteal phase support for...
Of the 231 enrolled patients, 222 completed the study.
The present systematic review and meta-analysis does not support a causal role between TS and adverse CV events.
It is concluded that atorvastatin is more potent than ezetimibe in improving the serum lipid profile, reducing oxidative stress, suppressing inflammation and preserving endothelial function, while ezetimibe may be advantageous...
Luteal phase administration of CC in patients with PCOS leads to increased follicular growth and endometrial thickness, which might result in a higher pregnancy rate.
Plasma OXA levels declined in lean volunteers and in type 1 diabetic patients injected with glucagon.
No correlations between these markers and LDL-cholesterol or CRP were observed.
Our data show, first, that azelnidipine, compared with amlodipine, exerted a favorable effect on sympathetic nerve activity, without affecting baroreflex sensitivity, in hypertensive patients.
Results showed combination therapy was safe and could gain better outcomes in blood sugar control.
Four years of early MHT did not affect progression of atherosclerosis despite improving some markers of CVD risk.
BMI status does not modify the effects of blood-pressure-lowering medications on BP control or heart and blood vessel disease outcomes.
Combination of CoQ10 and clomiphene citrate in the treatment of clomiphene-citrate-resistant PCOS patients improves ovulation and clinical pregnancy rates.
Incident AF is substantially less common among black than nonblack hypertensive patients.
In this trial, sertraline treatment was associated with superior effectiveness in relation to depressive, cognitive, and behavioral symptoms.
Although we were not able to confirm effects of gonadal hormone treatment on 5-HT₁A receptor binding, our data do not preclude associations between sex steroid levels and serotonin, the neurotransmitter implicated most...
In men with partial response to a PRN PDE5I, tadalafil 5 mg once daily significantly improved ED and sexual function vs placebo irrespective of testosterone levels.
The frequency of bathing did not seem to play an important role in the management of eczema.
Diane-35 may be a more suitable treatment option in adolescent girls diagnosed with PCOS when compared to MPA.
There is no difference between hypericum and placebo, regardless of the assumption about the missing data process.
Amlodipine reduced the risk of total heart and blood vessel events as well as all-cause mortality compared with non-CCB-based regimens, indicating its benefit for high-risk cardiac patients.
Primary analyses did not demonstrate that dual therapy outperformed both monotherapies in either timing of full symptom relief or full symptom relief rate.
Patients with OSA appear to have increased high cholesterol (high total cholesterol, LDL, TG, and low HDL).
At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of heart and blood vessel risks.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
